A trio of high-octane income stocks -- sporting an average yield of 6.65% -- can fatten investors' pocketbooks in 2025 (and ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment. It could begin competing with generic versions in the U.S. market in 2028, ...

There are some new tools to help this respiratory virus season: over-the-counter tests that can identify whether an illness ...

Invest in essential sectors like consumer staples and energy to beat inflation. See why these stocks offer reliable dividends ...

Come March, Medicare patients who meet income eligibility, which is at or below 300% of the Federal Poverty Level, and are ...

Pfizer Inc. (NYSE:PFE – Get Free Report) shares traded up 2.9% on Wednesday following a stronger than expected earnings ...

Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement ...

4Q Earnings: $410 million (loss of $3.4 billion 4Q24) ...

Dividend stocks are increasingly appealing for investors in 2025 due to their potential for steady income and resilience in ...

Pfizer reported better-than-expected quarterly profits on Tuesday behind cost cuts and growth in some non-Covid-related products including the blood clot drug Eliquis. Other pharmaceuticals with ...

Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...